Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 13/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118128 | 0.94 | F2 (0.49) | F2 | |
| SCHEMBL7115903 | 0.93 | F2 (0.46) | F2 | |
| SCHEMBL7121452 | 0.93 | F2 (0.46) | F2 | |
| SCHEMBL7120411 | 0.93 | F2 (0.46) | F2 | |
| SCHEMBL7115905 | 0.93 | F2 (0.44) | F2 | |
| SCHEMBL7121020 | 0.93 | F2 (0.46) | F2ALDH1A1NTRK1NTRK2 | |
| SCHEMBL7124406 | 0.93 | F2 (0.47) | F2 | |
| SCHEMBL7117072 | 0.92 | F2 (0.46) | F2 | |
| SCHEMBL7114667 | 0.90 | F2 (0.45) | F2NTRK1NTRK2 | |
| SCHEMBL7124457 | 0.89 | F2 (0.45) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656956-B2 | Tryptase inhibitor; antiinflamamtory agents, antiallergens | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | claimed |
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-06-05 | — | — | US | claimed |
| WO-2003028762-A1 | NOVEL ANTIMICROBIAL RESISTANCE BLOCKING COMPOSITIONS | ETHICON, INC. (US) | 2003-04-10 | — | — | WO | claimed |
| US-6656956-B2 | Tryptase inhibitor; antiinflamamtory agents, antiallergens | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | CMA1, TPSD1, TPSAB1 | F2 764/4885ALDH1A1 361/4885NTRK1 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.